Back to search

Peptide record

TPDB00100

Antibacterial Anticancer Antidiabetic Antifungal Antioxidant Antiparasitic standard
28 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB00100
Antibacterial Anticancer Antidiabetic Antifungal Antioxidant Antiparasitic
Anti-infective peptides Cardiometabolic peptides Cancer-related peptides Functional / health-promoting peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept
standard
No
A 28-aa standard natural multi-activity (Antibacterial, Anticancer, Antidiabetic, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
ALWKDILKNVGKAAGKAVLNTVTDMVNQ
Physicochemical Analysis
C133H225N37O39S1
RCEHFPSY
AKV
2998.53
10.16
4
2
14
+2
4.09
0.075
111.43
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
5500
183.42
6
Residue Composition
number
4
A
0
R
3
N
2
D
0
C
0
E
1
Q
2
G
0
H
1
I
3
L
4
K
1
M
0
F
0
P
0
S
2
T
1
W
0
Y
4
V
Amino Acid Distribution
A: 4 R: 0 N: 3 D: 2 C: 0 E: 0 Q: 1 G: 2 H: 0 I: 1 L: 3 K: 4 M: 1 F: 0 P: 0 S: 0 T: 2 W: 1 Y: 0 V: 4
Chemical Descriptors
28
C133H225N37O39S1
2998.53
10.16
+2
4.09
0.075
Evidence Records 21 records
Evidence 1 Activity

Activity

MIC
Antibacterial
3.0 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli A
Evidence 2 Activity

Activity

MIC
Antibacterial
4.6 µM

Target

Pseudomonas aeruginosa CIP A22

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli
Evidence 3 Activity

Activity

MIC
Antibacterial
11.6 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasin
Evidence 4 Activity

Activity

MIC
Antibacterial
5.0 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP DRAMP

Other

C 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasing peptide IRP from the skin of Phyll
Evidence 5 Activity

Activity

MIC
Antibacterial
2.3 µM

Target

Escherichia coli 54127

Source & Reference

dbAMP DRAMP

Other

4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasing peptide IRP from the skin of Phyllomedusa trinitatis frog shares t
Evidence 6 Activity

Activity

MIC
Antibacterial
5 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

t C-terminal amidation (Marenah L et al., 2004 Pancreas. Aug 29(2):110-5). Active against E. coli (MIC 5 uM) and S. aureus (MIC 3 uM) ( Proaño-Bolaños C et al., 2016 ). It has the potential to be de
Evidence 7 Activity

Activity

MIC
Antibacterial
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

(Marenah L et al., 2004 Pancreas. Aug 29(2):110-5). Active against E. coli (MIC 5 uM) and S. aureus (MIC 3 uM) ( Proaño-Bolaños C et al., 2016 ). It has the potential to be developed into molecules th
Evidence 8 Activity

Activity

MIC
Antifungal
3.0 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

Antifungipept

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli A
Evidence 9 Activity

Activity

MIC
Antifungal
4.6 µM

Target

Pseudomonas aeruginosa CIP A22

Source & Reference

Antifungipept

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli
Evidence 10 Activity

Activity

MIC
Antifungal
11.6 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

Antifungipept

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasin
Evidence 11 Activity

Activity

MIC
Antifungal
5.0 µM

Target

Escherichia coli ATCC 25922

Source & Reference

Antifungipept

Other

C 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasing peptide IRP from the skin of Phyll
Evidence 12 Activity

Activity

MIC
Antifungal
2.3 µM

Target

Escherichia coli 54127

Source & Reference

Antifungipept

Other

4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasing peptide IRP from the skin of Phyllomedusa trinitatis frog shares t
Evidence 13 Activity

Activity

MIC
Antifungal
5 µM

Target

Escherichia coli

Source & Reference

Antifungipept

Other

t C-terminal amidation (Marenah L et al., 2004 Pancreas. Aug 29(2):110-5). Active against E. coli (MIC 5 uM) and S. aureus (MIC 3 uM) ( Proaño-Bolaños C et al., 2016 ). It has the potential to be de
Evidence 14 Activity

Activity

MIC
Antifungal
3 µM

Target

Staphylococcus aureus

Source & Reference

Antifungipept

Other

(Marenah L et al., 2004 Pancreas. Aug 29(2):110-5). Active against E. coli (MIC 5 uM) and S. aureus (MIC 3 uM) ( Proaño-Bolaños C et al., 2016 ). It has the potential to be developed into molecules th
Evidence 15 Activity

Activity

MIC
Antiparasitic
3.0 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

NA

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli A
Evidence 16 Activity

Activity

MIC
Antiparasitic
4.6 µM

Target

Pseudomonas aeruginosa CIP A22

Source & Reference

NA

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli
Evidence 17 Activity

Activity

MIC
Antiparasitic
11.6 µM

Target

Pseudomonas aeruginosa ATCC 27853

Source & Reference

NA

Other

Active against S. aureus ATCC 25923 (MIC 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasin
Evidence 18 Activity

Activity

MIC
Antiparasitic
5.0 µM

Target

Escherichia coli ATCC 25922

Source & Reference

NA

Other

C 3.0 uM), P. aeruginosa CIP A22 (MIC 4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasing peptide IRP from the skin of Phyll
Evidence 19 Activity

Activity

MIC
Antiparasitic
2.3 µM

Target

Escherichia coli 54127

Source & Reference

NA

Other

4.6 uM), P. aeruginosa ATCC 27853 (MIC 11.6 uM) and E. coli ATCC 25922 (MIC 5.0 uM), and E. coli 54127 (MIC 2.3 uM). The insulin-releasing peptide IRP from the skin of Phyllomedusa trinitatis frog shares t
Evidence 20 Activity

Activity

MIC
Antiparasitic
5 µM

Target

Escherichia coli

Source & Reference

NA

Other

t C-terminal amidation (Marenah L et al., 2004 Pancreas. Aug 29(2):110-5). Active against E. coli (MIC 5 uM) and S. aureus (MIC 3 uM) ( Proaño-Bolaños C et al., 2016 ). It has the potential to be de
Evidence 21 Activity

Activity

MIC
Antiparasitic
3 µM

Target

Staphylococcus aureus

Source & Reference

NA

Other

(Marenah L et al., 2004 Pancreas. Aug 29(2):110-5). Active against E. coli (MIC 5 uM) and S. aureus (MIC 3 uM) ( Proaño-Bolaños C et al., 2016 ). It has the potential to be developed into molecules th